PR for science

Who Will Report Bio? with Danny Levine, Burrill & Company

Podcast Sponsor: Ingenuity - iReport, the fastest and most accurate way to get biological meaning from your expression data. iReport/


Danny Levine, Managing Director, Burrill&Company Bio and Contact Info

Listen (11:16) Consequences of few daily news reporters at BIO

Listen (5:59) Public trusts a daily reporter

Listen (6:57) Industry issues less about science and more about policy

Listen (2:11) A note about recent decision to uphold healthcare law

Listen (4:26) Role of scientists in today's world

Recently, more than 15,000 folks gathered in Boston for the annual BIO Convention, the largest gathering of the year for industry execs, national and local politicians, scientists and about anyone connected to the industry. However, this year there was a noticeable absence - a glaring lack of daily newspaper reporters. To discuss this and what it means for the industry we’re joined by Danny Levine, host of the popular podcast for the Burrill Report and managing director for Burrill’s Media division. In an article this week titled, “The Biotech Story You Won’t Read in Your Local Newspaper,” Danny wrote about the absence of the daily press at the event.

Danny also shares his thoughts about the recent ruling upholding the healthcare bill and weighs in on the role of scientists in today's world.

The Scientist's Buying Journey with Hamid Ghanadan, The Linus Group

Podcast Sponsor: Chempetitive Group - Adding "life" to life science marketing


Hamid Ghanadan, President, The Linus Group Bio and Contact Info

Listen (2:01) Genesis of the Linus Group

Listen (1:39) Dissonance between marketers and scientists?

Listen (9:41) How to market to scientists

Listen (4:23) What is content-centric marketing?

Listen (3:54) Demand generation

Listen (5:34) Company blogs- Are we all turning into journalists?

Listen (3:41) Dealing with 2012 marketing budget cuts

Listen (3:57) Pointers for using social media

Listen (2:24) New book out soon

Listen (4:03) Stereotypes of scientists

Today’s show is a must listen for anyone engaged in marketing in the life sciences. Hamid Ghanadan is President of The Linus Group, a marketing agency devoted to the life science industry. With a background in biochemistry, Hamid has created a unique company that specializes in understanding scientists and their buying behaviors. Hamid is also the editor and primary author of the Linus Report, the only publication offering critical briefings on science marketing issues.

Do Scientists have a Sense of Humor? With Brian Malow

This podcast was originally aired on March 1st, 2012

Sponsored by: BioConference Live


Brian Malow, Science Comdian Bio and Contact Info

Listen (3:53) Who is your audience?

Listen (6:28) Do scientists have a sense of humor?

Listen (4:41) Your worst audience ever

Listen (3:41) How do you do your research?

Listen (5:44) Similarity between science and comedy

Listen (1:50) Two bacteria walk into a bar...

Listen (3:53) Those dry scientific presentations

Listen (6:12) Communicating science to the public

Listen (3:36) Thoughts on the God particle

Listen (2:52) Have you had your genome sequenced?

Listen (1:10) Mating habits of scientists

Our guest today is Brian Malow, one of a rare species of science comedians. He has performed for NASA, JPL, AAAS, ACS, and many other acronyms, he says. Brian makes science videos for Time Magazine Online and is a contributor to Neil deGrasse Tyson’s radio show. He also gives workshops to train scientists to become better speakers. We’re excited to have him to mendelspod.

Looking Ahead to 2012 with Matthew Herper, Forbes

Podcast Sponsor: As the year takes off, we thank all our sponsors who have made mendelspod possible.

Affymetrix, Biotix, Epitomics, IDT, Ingenuity, Lab Roots, Laboratory Products Sales, Mo Bio, Science Exchange, Singulex, Traitwise


Matthew Herper, Science and Medicine Reporter, Forbes and Bio and Contact Info

Listen (4:17) More super expensive drugs

Listen (5:48) New genetic technologies to face the valley of death

Listen (1:15) Health IT will stall

Listen (4:15) Winning companies of 2011

Listen (3:09) Are we seeing innovation in big pharma model?

Listen (1:38) VC funding

Listen (6:56) Cancer's moment of promise and chaos

Listen (6:00) I like telling stories about science

Listen (4:38) Bill Gates changes the world again

Listen (6:09) Will 2012 political environment be good for life science?

Noted life science reporter, Matthew Herper, from Forbes looks into his crystal ball. Join us as we discuss important trends going into 2012 with a look back at those companies who did well in 2011. In November, Herper wrote a cover article for Forbes, "With Vaccines, Bill Gates Changes the World Again." Herper shares thoughts on his two interviews with Gates, commenting on the potential for the vaccine industry. Herper has an impressive perspective on the commercial side of the industry; what's having practical financial success, and what isn't.

NOTE: Matt spends some time here talking about Dendreon and the disappointing sales of their cancer drug Provenge. Shortly after our interview, Dendreon announced 4th quarter sales which beat analysts' expectations and boosted their stock immediately by 40%.

Best of mendelspod - Highlights 2011

Podcast Sponsor: Ingenuity- iReport: The fastest way to get meaning from your expression data

Listen (3:50) Steve Burill: New Model for Big Pharma

Listen (7:06) Dan Vorhaus: The Myriad Case

Listen (3:36) Russ Altman: Personal Genomics and Patent Law

Listen (3:43) Mike Snyder: Million Dollar Interpretation

Listen (2:50) Howard McLeod: PGENI

Listen (2:08) Jonathan Eisen: Why Open Science?

Listen (3:12) George Church: Scientists and the Public

Listen (4:25) Ron Davis: Fit Between University and Industry

Listen (3:01) Greg Scott-Will China Soon Have a Steve Jobs?

As we approach the last day of 2011, we thought we’d look back and bring you highlights of the year, the very best of mendelspod. Included in today’s show are snippets from industry leaders on personalized medicine, the evolution of big pharma, gene patents, and thoughts on open science.

NOTE: It’s important to acknowledge that mendelspod has been made possible through the generous support of our sponsors throughout the year. We thank all of them for their partnership. We wish them and all of you a very happy holiday.

History as a Bridge to the Future: LSF Launches Book on Genentech

Last month, while interviewing Steve Burrill, he introduced me to a new organization which he chairs, The Life Sciences Foundation (LSF). “What we want to do with the Foundation is to tell the real story of what happened,” he told me. “History and information are different. History is putting the information in a context that makes it useful in the future. Young people today don’t know who Cetus Corporation was.”

The Foundation

George Church Talks Personalized Medicine and Synthetic Biology

This podcast originally aired on May 25th, 2011

Sponsored by: BioConference Live

Guest: Church George, PhD, Professor of Genetics, Harvard Medical School and Professor of Health Sciences & Technology, Harvard and MIT. Bio and Contact Info

Part I-Personalized MedicineChurch George Listen (20:24)

Part II-Synthetic BiologyChurch George Listen (19:04)

Part III-Personal AnecdotesChurch George Listen (06:54)

Our guest for the hour is Dr. George Church from Harvard. Dr. Church’s accomplishments are legendary among scientists in his field and beyond. His Ph.D. from Harvard in biochemistry and molecular biology with Wally Gilbert included the first direct genomic sequencing method in 1984. In 1994, the technology transfer of automated sequencing and software to Genome Therapeutics Corp. resulted in the first commercial genome sequence (the human pathogen, H. pylori). He was then involved in initiating the Human Genome Project as a Research Scientist at Biogen Inc. In 2006 he initiated the Personal Genome Project with the aim of advancing the field of Personalized Medicine. He invented the broadly-applied concepts of molecular multiplexing and tags, homologous recombination methods, and array DNA synthesizers. He has served in advisory roles for 12 journals and 5 granting agencies and also been involved in 22 private companies including LS9-which focuses on bio-petroleum, and Knome who provides full human genome sequencing. Current research focuses on integrating biosystems-modeling with personal genomics and synthetic biology.

Welcome to!

Here’s how it works. We produce fascinating shows on highly relevant topics, and you come and listen. You, the researcher at the university lab, you, the researcher in the small biotech start-up or in the large pharma lab, you, the management for the growing diagnostics company or you, the doctor wishing to know what is new in genetic research. Log on and play the podcast at any time, anywhere in the world. Hear from someone in the show that you’d like to contact? Go to Guests and there you’ll find them listed with contact information. Follow my blog here.